BMY Analyst Ratings
Bristol-Myers Squibb Company (BMY) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry, with a market capitalization near $115.76B, listed on NYSE, employing roughly 32,500 people, carrying a beta of 0.23 to the broader market. Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. Led by Christopher Boerner, public since 1972-06-01.
Analyst Ratings
In the October 2026 monthly count, 30 analysts rated BMY: 4 Strong Buy, 7 Buy, 18 Hold, 1 Sell and 0 Strong Sell.
Twelve months earlier, in October 2025: 26 analysts, 3 Strong Buy, 3 Buy, 19 Hold, 1 Sell and 0 Strong Sell.
Price Targets
- Average Target
- $66.08
- Median Target
- $65.00
- High
- $82.00
- Low
- $41.00
- Targets Published, Last 12 Months
- 30
Recent Price Targets
The 5 most recent of 30 price targets published in the last 12 months.
| Date | Firm | Analyst | Target | Price When Posted |
|---|---|---|---|---|
| Oct 12, 2026 | Jefferies | Akash Tewari | $76.00 | $57.58 |
| Oct 8, 2026 | Cantor Fitzgerald | Carter Gould | $53.00 | $59.70 |
| Oct 7, 2026 | Morgan Stanley | Terence Flynn | $41.00 | $59.70 |
| Oct 5, 2026 | Leerink Partners | Not named | $59.00 | $59.02 |
| Sep 23, 2026 | Goldman Sachs | Asad Haider | $63.00 | $62.25 |
Recent Upgrades & Downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Oct 8, 2026 | Cantor Fitzgerald | maintain | Neutral | Neutral |
| Oct 7, 2026 | Morgan Stanley | maintain | Underweight | Underweight |
| Oct 5, 2026 | Leerink Partners | downgrade | Outperform | Market Perform |
| Sep 16, 2026 | Piper Sandler | maintain | Overweight | Overweight |
Quantitative Rating
BMY carries a model grade of A- (overall score 4 of 5), computed from six valuation and financial measures (discounted cash flow, return on equity, return on assets, debt to equity, price to earnings and price to book), each scored 1 to 5. It is not an analyst rating.
How to Read BMY Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked BMY analyst ratings questions
- What is the BMY consensus price target?
- As of the latest aggregator update, Bristol-Myers Squibb Company (BMY) carries a consensus 12-month price target of $66.08. Target ranges run from a low of $41.00 to a high of $82.00. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on BMY?
- In the October 2026 monthly count, 30 analysts rated BMY, and the distribution is concentrated at Hold: 4 Strong Buy, 7 Buy, 18 Hold, 1 Sell and 0 Strong Sell. Rating consensus moves slowly relative to price; it reflects sell-side conviction over a 12-month horizon rather than near-term momentum.
- What recent ratings actions has BMY seen?
- The five most recent ratings actions on BMY appear on the page above. Sell-side rating changes are watched for two reasons: an upgrade or downgrade with a meaningful target revision moves the consensus and can trigger short-term positioning shifts, and the firm-level rating cluster (multiple firms moving in the same direction within a short window) is a clearer signal than any single action. Options markets often price the implied-vol response within minutes of the announcement.
- How do analyst targets affect BMY options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.